Compare Fox Corp Class B (FOX) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Repligen Corporation Common Stock — how do they compare? Fox Corp Class B trades at $55.56 (market cap $24.91B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Fox Corp Class B is far larger — about 2.2× Repligen Corporation Common Stock's market cap, and Fox Corp Class B pays a 1.04% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and Repligen Corporation Common Stock for 0 Days on average.
| FOX | RGEN | |
|---|---|---|
Market Cap | $24.91B | $11.14B |
Volume | 395,394 | 1,259,263 |
Sector | Media | Health |
52-Week High | $67.76 | $194.57 |
52-Week Low | $44.39 | $102.87 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $28.27B | $11.02B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX trades at $55.93, down 0.09% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.79 beating expectations of $1.44, and fundamentals show robust revenue growth to $16.30 billion in 2025 and a net income margin of 13.88%. Analyst consensus is a buy with a price target of $84.75, implying significant upside. A dividend of $0.29 per share is scheduled for payment on September 23, 2026.
The outlook for FOX is positive based on solid fundamentals and analyst optimism, but risks include a projected decline in net income margin to 9.83% in 2026 and bearish technical indicators. The stock offers value with a P/E of 14.56 and growth potential, though investors should monitor earnings consistency and market sentiment shifts.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
